Stories are generated from ORTEX data and reviewed by the ORTEX team. How we publish
FCX heads into its October 23 earnings report with a wave of analyst upgrades and a short position that has quietly doubled since early September, creating an unusual backdrop where institutional conviction is rising even as bearish bets accumulate.
The most striking development this week is the breadth and scale of analyst target lifts. JP Morgan's Bill Peterson raised his target to $92 from $77 on October 7 while maintaining Overweight, the boldest call in a sweep of upward revisions. Wells Fargo lifted its target to $87 from $70 on October 6, and Citi moved to $84 from $66 on October 5. Barclays added a token increment to $83. Morgan Stanley held Equal-Weight but nudged its target to $75 from $70. The overall direction is unambiguous: five firms raised targets within three days, and the consensus mean has climbed to $76.64 against a current price of $72.56. JP Morgan's $92 target stands out as an outlier on the bullish end, while a lone Bernstein note from late September cut its target to $47, well below the pack, and represents the only meaningful dissenting voice in recent months. Bernstein's $47 reads as a stark contrast given the current price, and with that note now approaching four weeks old, it may reflect a different copper price assumption than peers are running.
The bull case centres on Grasberg. Freeport controls the world's largest copper mine and holds rights through the life of the resource following its agreement with the Indonesian government. Production is forecast to remain strong through 2030, and the free-cash-flow profile is seen supporting increased shareholder returns. Bears point to the same geography as the key risk: Indonesian political instability, the need for near-term funding solutions, and a stock that trades at a premium to copper peers. At roughly 18x trailing earnings and 7.5x EV/EBITDA, FCX is not cheap on a historical basis. EV/EBITDA has compressed about 0.35 turns over the past 30 days as the stock has lagged somewhat, down just over 0.2% for the month despite the analyst enthusiasm. EPS momentum scores rank in the 72nd and 78th percentiles at 30 and 90 days, pointing to solid upward earnings revisions, though the 12-month forward year-on-year EPS growth ranks only in the 46th percentile, modest for a name trading at this multiple.
Short interest tells a more cautious story beneath the bullish analyst surface. Shorts have grown roughly 35% over the past month, from around 25.5 million shares in early September to 34.5 million now, bringing the position to 2.4% of free float. That absolute level is low and not alarming in isolation, but the pace of accumulation is notable: in mid-September a step-change added roughly four million shares in a single session, and the position has ground higher every week since. Despite that build, the borrow market remains completely untroubled. Availability is essentially unlimited, with over 820 million shares available to lend against a short position of 34 million. Borrowing costs are minimal at 0.37% annualised, easing 15% on the week even as the position grew. There is no squeeze pressure here. Options positioning is also calm: the put/call ratio of 0.93 is slightly below its 20-day average of 0.95 and well within the year's range of 0.77 to 1.09. The ORTEX short score has edged up from 31.1 to 32.3 over the past two weeks, a gentle drift rather than a sharp signal.
On the institutional side, the register is broadly constructive. BlackRock, Vanguard and State Street together hold around 20% of shares, and State Street added 2.3 million shares in its most recent report to September 30. JP Morgan Asset Management added 8.8 million shares in the same period, one of the larger recent position builds among the top holders. Insider activity is less directional: the net 90-day position across all disclosed trades is a small net sale of around $8.4 million, but the bulk of that reflects the EVP and General Counsel exercising and then selling options in late August, a compensation-driven transaction rather than a conviction call. Two directors received small stock grants on October 1. Wikipedia attention for FCX is running roughly two standard deviations above its own 90-day average, the highest retail attention reading in recent months, which may reflect the copper price move and the analyst commentary landing in the same week.
FCX's closest peers had a mixed week. SCCO dipped 0.5% on the day and gained 0.8% for the week. GMEXICO B rose 3.1% on the week, outpacing FCX's own 2.5% gain, while Ivanhoe Mines fell 2.4%. The copper complex is broadly positive on the week but not uniformly so, and FCX's outperformance since the start of the year remains the defining feature of the group.
With Q3 results due October 23, the next 16 days will clarify whether the wave of analyst target lifts was pricing in a copper market improvement that the actual production numbers will either confirm or contradict.
See the live data behind this article on ORTEX.
Open FCX on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data and reviewed by the ORTEX team. Content is informational only and does not constitute investment advice.